Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
G D Searle
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Medications for the prophylaxis of opportunistic infections, such as:
Aerosolized pentamidine.
Trimethoprim/sulfamethoxazole.
Nystatin.
Clotrimazole.
Anti-mycobacterial agents.
Ganciclovir.
Topical acyclovir.
Patients must have the following:
CD4+ cells counts = or \> 200 \< 500 /cell mm3.
For purposes of inclusion the absolute CD4+ cell count must be = or \> 200 \< 500 cells/mm3 on the first sample and = or \> 190 \< 510 cells/mm3 on the second sample.
Have at least one of the following:
Oral candidiasis.
Herpes zoster during the last 3 years.
Oral hairy leukoplakia during the past three years.
Chronic ( \> 30 day period), recurrent seborrheic dermatitis, or topical, pruritic folliculitis (itchy bumps).
Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight.
Chronic fatigue present for the past 6 months, which has interfered with normal activity at least 1 to 2 times per week.
HIV antibody positive as determined by federally licensed Enzyme-linked Immunosorbent Assay (ELISA).
Documented, written informed consent must be obtained prior to admission to the study.
Prior Medication:
Allowed for no more than 12 weeks prior to study entry:
Zidovudine (AZT).
You may not be if
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Malignancies, with the exception of basal cell carcinoma.
Significant organ dysfunction.
Concurrent Medication:
Excluded:
All anti-retroviral drugs with the exception of Zidovudine. Cancer chemotherapeutic agents.
Anti-metabolites and alkylating agents.
All investigational non-FDA approved drugs.
Patients with the following are excluded:
Clinically significant diarrhea (\> 3 liquid stools per day for \> 7 days) without definable cause, within 6 months prior to enrollment).
Diarrhea, as above, with known, non-HIV related cause occurring within one month prior to enrollment.
Meets CDC criteria for AIDS classification.
Chronic fever (\> 38.5 C persisting for more than 14 consecutive days, or for more than 15 days in any 30-day interval prior to study entry).
Malignancies, with the exception of basal cell carcinoma.
Significant organ dysfunction.
Known hypersensitivity to SC-48334 or related compounds.
History of lactose intolerance.
Prior Medication:
Excluded within 30 days of study entry:
Any investigational medication.
Treatment with a drug (other than Zidovudine) with anti-HIV activity.
Excluded for \> 12 weeks prior to study entry:
Zidovudine (AZT).
Excluded within 90 days of study entry:
Ribavirin.
Excluded within 6 months of study entry:
Cancer chemotherapy.
Excluded:
Treatment with SC-48334.
Prior Treatment:
Excluded within 30 days of study entry:
Electron beam radiation.
Excluded within 6 months prior to study entry:
Required HIV-related blood transfusions.
Whole body radiation.
Current use of illicit substances; or current abuse of alcohol, the use of which would limit compliance with the protocol.
Clareo Health | Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
